Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Ottawa Conference and Event Centre

Nov 07, 2023 7:30 AM - Nov 08, 2023 4:10 PM

200 Coventry Road, Ottawa, ON K1K 4S3, Canada

Canada Annual Meeting

The Canada Annual Meeting offers Three Tracks, Regulatory, Clinical, Pharmacovigilance!

Session 5, Track A: Accelerating Access to Medicines Through Collaboration

Session Chair(s)

Yatika  Kohli, PhD, MBA

Yatika Kohli, PhD, MBA

Chief Regulatory and Strategy Officer

NoNO Inc, Canada

Tharany  Ganesh, MSc

Tharany Ganesh, MSc

Head, Regulatory Affairs

AstraZeneca Canada Inc., Canada

Amber  McLeod, PhD

Amber McLeod, PhD

Immunology, Virology, and Specialty Head, Regulatory Affairs

Abbvie Corporation, Canada

This session will focus on some international collaboration initiatives in place to support timely access to medicines in Canada. On behalf of the ACCESS (Australia, Canada, Singapore, Switzerland and United Kingdom) Consortium, Health Canada will provide updates on the ongoing work of Access New Active Substance Work group (NAS WG) including statistics, in addition to providing an update on the newly created Promise Pathway. At this session, representatives from innovative Medicines Canada (IMC) will share the findings of its survey of members’ experiences with submissions reviewed through this initiative as well as speak to the additional initiatives being taken by IMC to accelerate access to medicines for Canadians.

Learning Objective :
  • Understand the key performance indicators and measures of the Access NAS WG from a regulator’s perspective
  • Gain awareness of the advantages, limitations and recommendations to enhance participation in the NAS WG from an industry perspective
  • Explain additional IMC initiatives to accelerate access to medicines for Canadians

Speaker(s)

Jeffrey  Skene, MSc

Access: Feedback from 5 Country Survey and Update from Health Canada

Jeffrey Skene, MSc

Health Canada, Canada

Director, Bureau of Cardiology, Allergy and Neurological Science

Laura  King, MBA

Access: Feedback from 5 Country Survey and Update from Health Canada

Laura King, MBA

Innovative Medicines Canada, Canada

Vice Chair, Regulatory Operations Teams

Shirley  Hopper, DrMed

International Recognition Procedure (IRP)

Shirley Hopper, DrMed

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Deputy Director, Innovative Medicines, HQA

Jonathan  Feairs

Enabling Patient Access via Policy Innovation

Jonathan Feairs

AstraZeneca Canada, Canada

Director, Government Affairs & Public Policy

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.